POSTRESECTION RECURRENCE OF HEPATOCELLULAR-CARCINOMA TREATED BY ARTERIAL EMBOLIZATION - ANALYSIS OF PROGNOSTIC FACTORS

被引:53
作者
TAKAYASU, K
WAKAO, F
MORIYAMA, N
MURAMATSU, Y
YAMAZAKI, S
KOSUGE, T
TAKAYAMA, T
OKADA, S
OKAZAKI, N
MAKUUCHI, M
机构
[1] NATL CANC CTR,DEPT SURG,TOKYO 104,JAPAN
[2] NATL CANC CTR,DEPT INTERNAL MED,TOKYO 104,JAPAN
[3] SHINSHU UNIV,SCH MED,DEPT SURG 1,MATSUMOTO,NAGANO 390,JAPAN
关键词
D O I
10.1002/hep.1840160409
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Of 270 consecutive patients with hepatocellular carcinoma who underwent surgery, 50 who had recurrence and were subsequently treated with transcatheter arterial embolization were analyzed. The longest interval between surgery and recurrence in the 50 patients who underwent transcatheter arterial embolization was 7 yr. Recurrence was initially found in the remnant liver in all patients but one; extrahepatic metastases were detected in 13 patients (26%) during follow-up. A "multiple" type was the most common (64%) hepatic recurrence pattern on angiography, followed by the "solitary" (16%) and "tumor thrombus" (12%) patterns. Hepatic recurrence was most frequently found in the ipsilateral lobe (48%) relative to the site of the primary hepatocellular carcinoma. Multivariate analysis of the factors affecting survival after transcatheter arterial embolization indicated that recurrence pattern (p = 0.025) and distant metastases (p = 0.011) were significant. Of 13 patients with distant metastases, 11 had the "multiple" pattern of hepatic recurrence. Survival rates for all 50 patients after initial surgery and after transcatheter arterial embolization were 90% and 64%, respectively, at 1 yr; 52% and 24%, respectively, at 3 yr; and 27% and 5%, respectively, at 5 yr. On analysis of survival rates after transcatheter arterial embolization in 37 patients with recurrence only in the liver and of the response of recurrent hepatocellular carcinoma to transcatheter arterial embolization, a significant difference was noted between those with "partial response" and "progressive disease" (p < 0.05) and between those with "no change" and "progressive disease" (p < 0.05).
引用
收藏
页码:906 / 911
页数:6
相关论文
共 24 条
[1]   INTRAHEPATIC RECURRENCE AFTER RESECTION OF HEPATOCELLULAR-CARCINOMA COMPLICATING CIRRHOSIS [J].
BELGHITI, J ;
PANIS, Y ;
FARGES, O ;
BENHAMOU, JP ;
FEKETE, F .
ANNALS OF SURGERY, 1991, 214 (02) :114-117
[2]   HEPATOCELLULAR-CARCINOMA AND HEPATITIS B-VIRUS INFECTION - MOLECULAR EVIDENCE FOR MONOCLONAL ORIGIN AND EXPANSION OF MALIGNANTLY TRANSFORMED HEPATOCYTES [J].
BLUM, HE ;
OFFENSPERGER, WB ;
WALTER, E ;
OFFENSPERGER, S ;
WAHL, A ;
ZESCHNIGK, C ;
GEROK, W .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1987, 113 (05) :466-472
[3]  
Child CG TJ, 1964, LIVER PORTAL HYPERTE, P50
[4]  
ESUMI M, 1986, CANCER RES, V46, P5767
[5]  
IKEYA S, 1990, JPN J CANC CLIN, V36, P985
[6]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]  
Liver Cancer Study Group of Japan, 1990, Ann Surg, V211, P277
[8]   2ND HEPATIC RESECTION FOR RECURRENT HEPATOCELLULAR-CARCINOMA [J].
NAGASUE, N ;
YUKAYA, H ;
OGAWA, Y ;
SASAKI, Y ;
CHANG, YC ;
NIIMI, K .
BRITISH JOURNAL OF SURGERY, 1986, 73 (06) :434-438
[9]  
NAGASUE N, 1982, SURG GYNECOL OBSTET, V155, P697
[10]  
NAKASHIMA T, 1983, CANCER, V51, P863, DOI 10.1002/1097-0142(19830301)51:5<863::AID-CNCR2820510520>3.0.CO